Hi Jim, thanks for your insight. Do you happen to know the market potential for Fampridine-SR? Any projections you can share with everyone? Thanks in advance.

Very insightful analysis. Thanks. My only concern is that the technology is still in early stages of development, and I don't see Belviq revenues rising significantly any time soon. Thus, unless Arena announces a partnership or acquisition, I don't see the share price rising beyond what occurred in the past several days. Do you see the stock price increase as an indication that shareholders believe the company could be acquired, considering Arena's potential to develop treatments targeting major indications? Do you think the share price increase is warranted? Thanks in advance.

Hi Alpha Stockman, thanks for your comment. In addition to the disclosure I've provided above, I will say that I have no interest in Quicklegal, nor do I have any relations with the company. However, my brother, Justin Lowenthal, was former general counsel for Quicklegal. That is how I discovered the startup. This article was not written at his direction nor the company's.

I thought about writing on the company in late 2014, but never got to it. But when Quicklegal recently won first place at the TechWeek competition, I made it a priority. I hope you enjoyed the article.

Best,

Trevor

Hi Duke, according to nationalmssociety.org,

"Based on data in animal studies, the prescribing information also contains a boxed warning indicating that Aubagio may cause significant birth defects if used during pregnancy. Aubagio should not be taken by women who are pregnant or by women of childbearing age who are not using effective birth control. Women taking Aubagio who wish to become pregnant should stop taking the medication and undergo an accelerated elimination procedure to decrease the level of Aubagio in the blood to a safe level (less than 0.02 mg/L)."

To sum things up, patients are encouraged to practice contraception while taking Aubagio due to the risk of birth defects.

Thanks,

Trevor

I will reach out to the editor to make corrections. Thanks for pointing this out to everyone.

Best, Trevor

Hi Kole, you are certainly right. That was a misstatement: it should read "patients taking Aubagio are [encouraged]...

Hi Kole, thank you for pointing that out. Let me check my sources on that and I'll get back to you ASAP. I'll make edits accordingly. Best, Trevor.

Hi Liz, Thanks for the followup. I completely agree with you on that. I apologize for not emphasizing that point. I myself was adversely affected by the misconception about the Phase 2 readout. I have been an SYN holder for roughly 3 years. Thanks so much for clarifying. I encourage you to write an article on SYN discussing the confusion surrounding Trimesta etc.

Best wishes,

Trevor

Hi Liz, I appreciate your insight. I am well aware of the reasons for the improvement, but I don't believe I misinterpreted the results at all. I stated in the article that the trial was not powered to reach significance in year two. I did mention a drop in improvement because that is what management stated in the readout. However, I do believe that the lack of significance at year two irrespective of the lack of power to reach significance in year two is the reason for the sharp drop in PPS following the readout(s). That is what a late stage study is for, correct? I am no scientist, but I am very familiar with clinical trials and interpreting trial results. Thanks for reading.

Best,

Trevor

You bet!